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Abstract Patients with moderate to severe psoriasis are
undertreated. To solve this persistent problem, the consen-
sus programme was performed to deﬁne goals for treatment
of plaque psoriasis with systemic therapy and to improve
patient care. An expert consensus meeting and a collabo-
rative Delphi procedure were carried out. Nineteen der-
matologists from different European countries met for a
face-to-face discussion and deﬁned items through a four-
round Delphi process. Severity of plaque psoriasis was
graded into mild and moderate to severe disease. Mild
disease was deﬁned as body surface area (BSA) B10 and
psoriasis area and severity index (PASI) B10 and derma-
tology life quality index (DLQI) B10 and moderate to
severe psoriasis as (BSA[10 or PASI[10) and
DLQI[10. Special clinical situations may change mild
psoriasis to moderate to severe including involvement of
visible areas or severe nail involvement. For systemic
therapy of plaque psoriasis two treatment phases were
deﬁned: (1) induction phase as the treatment period until
week 16; however, depending on the type of drug and dose
regimen used, this phase may be extended until week 24 and
(2) maintenance phase for all drugs was deﬁned as the
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DOI 10.1007/s00403-010-1080-1treatment period after the induction phase. For the deﬁnition
of treatment goals in plaque psoriasis, the change of PASI
from baseline until the time of evaluation (DPASI) and the
absolute DLQI were used. After induction and during
maintenance therapy, treatment can be continued if reduc-
tion in PASI is C75%. The treatment regimen should be
modiﬁed if improvement of PASI is\50%. In a situation
where the therapeutic response improved C50% but\75%,
as assessed by PASI, therapy should be modiﬁed if the
DLQI is[5 but can be continued if the DLQI is B5. This
programme deﬁnes the severity of plaque psoriasis for the
ﬁrst time using a formal consensus of 19 European experts.
In addition, treatment goals for moderate to severe disease
were established. Implementation of treatment goals in the
daily management of psoriasiswill improve patient care and
mitigate the problem of undertreatment. It is planned to
evaluate the implementation of these treatment goals in a
subsequent programme involving patients and physicians.
Keywords Psoriasis  Treatment goals  Severity 
Patient care  Consensus
Introduction
Psoriasis is a chronic, immune-mediated inﬂammatory
disorder affecting 2–3% of the Caucasian population in
western countries [14]. Treatment of psoriasis can provide
skin clearance but not a cure. In limited (mild) disease, the
most commonly used therapy is topical with the addition of
phototherapy in refractory cases. In moderate to severe
psoriasis, phototherapy alone, combined with systemic
therapy or systemic therapy alone is recommended. Recent
guidelines present the level of evidence for the efﬁcacy of
the available therapies and give recommendation for their
use in daily practice [12, 16, 23–25].
Despite the availability of a number of treatment
options, surveys have shown that patients with psoriasis do
not receive the optimal care that is necessary to clear their
skin symptoms and to improve their health-related quality
of life (HRQOL). Patients are frequently left on treatments
for too long even though they may be ineffective. In gen-
eral, dermatologists are reluctant to use systemic therapies
[13].
The aim in deﬁning treatment goals in psoriasis was to
improve patient care with a major emphasis on HRQOL [3,
18]. In guidelines for treatment, drugs and therapeutic
procedures are evaluated on the basis of the published
clinical trial data. There is, however, no generally accepted
consensus deﬁnition of either treatment success or failure.
In patient care, there is a necessity to decide whether a drug
or procedure is able to improve the disease at a given point
of time. However, there is still a lack of a deﬁnition of a
sufﬁcient improvement in an individual patient’s disease,
but it likely depends on a combination of the drug’s
effectiveness, convenience and safety and patient-reported
outcomes such as preference, satisfaction and improvement
in HRQOL.
Whether a therapy is successful or not is directly linked
to an action resulting from such a judgement which in
effect means either continuation of therapy or modiﬁcation
of the therapeutic regimen.
Therefore, the deﬁnition of treatment goals is essential
for maintaining a high standard of care. In a survey among
dermatologists in Germany, psoriasis patients presented
with a mean psoriasis area and severity index (PASI) of 12
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123(moderate to severe disease) while under continuous care
[1]. These data clearly indicate that psoriasis patients are
both undertreated and underserved. A likely cause for this
dilemma is the lack of treatment goals with an integrated
demand for action.
It was the aim of this project to elaborate deﬁnitions for
psoriasis severity and to deﬁne treatment goals on the basis
of a European consensus. The programme included pre-
paratory work and guidance by a steering committee, a
consensus meeting with face-to-face discussion and
establishment of the consensus by a Delphi procedure.
Experts from 19 European countries participated in this
programme. The work supplements existing guidelines
such as the European Guideline on the treatment of pso-
riasis, the Dutch guideline, the German S3-guideline and
the recent guidelines of the British Association of Der-
matologists for the use of biologic therapies in psoriasis
[12, 16, 23–25].
Common tools to score psoriasis include the determi-
nation of the area involved in relation to the whole body
surface (body surface area, BSA), the psoriasis area and
severity index (PASI) which evaluates lesions by their
characteristics of erythema, induration and scaling as well
as by the surface area affected and the physician’s global
assessment (PGA) aiming for an overall evaluation of
lesion severity. In Europe, the PASI is a commonly used
tool to grade psoriasis severity and is used in the majority
of international clinical trials as primary or secondary
endpoint. This score, despite some methodological limita-
tions, is most useful in patients with moderate to severe
psoriasis and has been shown to be a reliable instrument to
evaluate treatment success or failure when patients are
scored at baseline before treatment initiation and while on
therapy [26]. The most commonly used outcome parame-
ters to assess the impact of the disease on quality of life are
the dermatology life quality index (DLQI) and the Skin-
dex-29 [4]. The DLQI is a widely used scale which has
been translated in all languages represented in the con-
sensus programme and is available online free of charge for
academic and ofﬁce use [7].
There is no commonly accepted deﬁnition of limited
(mild) versus moderate or severe psoriasis. In a consensus
statement from the National Psoriasis Foundation [15], a
group of North American experts divided plaque psoriasis
into ‘‘candidates for localized therapy’’ with a BSA\5
and ‘‘candidates for systemic and/or phototherapy’’
(BSA C 5). In addition, the ‘‘rule of tens’’ deﬁning current
severe psoriasis (BSA[10 or PASI[10 or DLQI[10)
was suggested as a tool to grade clinical severity [8].
A clear deﬁnition of psoriasis severity has tremendous
implications for a number of clinical decisions related to its
management. These include therapeutic concepts and
pharmacoeconomics.
The outcome of this consensus programme represents, to
the best of our knowledge, the ﬁrst deﬁnition of severity
and of treatment goals in a chronic disorder based on a
broad consensus established by a formal procedure. These
consensus recommendations should lead to an improve-
ment in the care of psoriasis patients. In order to evaluate if
these aims are met, it is planned to evaluate the proposed
treatment goals in a subsequent programme involving
patients and dermatologists.
Methods
Structure of the European consensus programme
The goal of the programme was to produce European
consensus on ‘‘Treatment goals for psoriasis’’. This is the
opposite of a systematic collection of arguments and
alternatives without the necessity to get consensus.
Two formal consensus methods were used: a consensus
conference and the Delphi technique.
The Delphi technique can be characterized as a method
for structuring a group communication process, thereby
facilitating its ability to deal with a complex problem. To
accomplish this structured communication there should be:
some feedback of individual contributions of information
and knowledge; assessment of the group’s judgment or
view; opportunities for individuals to revise views; a cer-
tain degree of anonymity for the individual responses and
repetition [10].
Formal methods of consensus development are used
because several people are less likely to arrive at a wrong
decision than a single individual, and a selected group of
individuals is more likely to lend some authority to the ﬁnal
decision. Furthermore, by providing a structured process,
formal methods can eliminate negative aspects of group
decision-making, and formal consensus methods meet the
requirements of scientiﬁc methods. The advantage of the
Delphi procedure is the formalized and recognized meth-
odology, providing a structured group communication
process. In our programme, we agreed to use the collabo-
rative Delphi procedure in which the number of partici-
pants is manageable, and outputs/next steps are driven by
the panel of participants.
All preparatory work including the deﬁnition of the
structure and work ﬂow was done by a steering committee
(K.K., K.R., P.S. lead by U.M.) assisted by A.N. and J.F.
C.E.M.G. served as a reviewer of the programme and of the
ﬁnal manuscript draft.
The consensus group consisted of dermatology experts
on psoriasis management from 19 European countries.
Each participant was chosen according to her/his recogni-
tion in the ﬁeld or was nominated by their respective
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the consensus meeting held in Hamburg, Germany, Feb-
ruary 12, 2009 was mandatory. Participants had to disclose
their conﬂicts of interest and were able to vote for decisions
made at the consensus meeting or later in the Delphi pro-
cedure. It was decided by the group that the Delphi pro-
cedure should not be anonymous. The members of the
steering committee, programme reviewer and the assistants
were excluded from voting in the Delphi rounds.
The programme was supported by an unrestricted edu-
cational grant from Abbott to the University Medical
Center Schleswig-Holstein Campus, Kiel, Germany. The
sponsor had no inﬂuence on the programme at any time.
All ﬁnancial transactions (e.g. reimbursement of travel
costs, etc.) were processed through the ﬁnance department
of the grant designee.
The consensus process started with presentations of
the steering group at the consensus meeting. Comments
and feedback were given on the initial steering group
statements, and the rating of the importance of different
steps to come to treatment goals was discussed. Agree-
ments and disagreements were discussed, and the reasons
and evidences behind these and alternative statements
were developed. The full Delphi process consisted of four
rounds. In the ﬁrst Delphi round, structured questions
were formulated on the issues to be addressed. An intro-
duction was provided to explain how to ﬁll out the
questionnaire. Some background information was pro-
vided based on evidence and the knowledge of the
steering group (from the second until the fourth round
further development of questions was also based on par-
ticipants’ comments). In the ﬁrst rounds for most ques-
tions two or more answers were possible; in subsequent
rounds, fewer options were available. If agreement was
achieved on certain items, this was mentioned in the text
of the subsequent round questionnaire, and no more voting
occurred on these.
Questionnaires sent out to the consensus group partici-
pants had to be completed and returned within 10 days of
receipt (Fig. 2).
By deﬁnition, a vote of at least 17 out of 19 for
acceptance of an item represented a strong consensus and
was regarded as ‘‘agreement’’. The time between the
rounds ranged between 5 and 10 weeks. The data man-
agement was descriptive.
Results
Deﬁnition of strength of agreement
It was agreed by the group that if 90% of the participants
voted for an item this was deﬁned as strong consensus or
‘‘agreement’’. By mathematical means, a vote of 17 out of
19 represents an 89.47% agreement. In Delphi round 3,
there was a formal vote of all participants to regard a vote
of 17 or more out of 19 as strong consensus or
‘‘agreement’’.
‘‘A vote of 17 or more out of 19 voters is regarded as
a strong consensus and equals 90% (‘agreement’)’’.
(Delphi-result: vote 19/19 = agreement, round 3)
Severity of plaque psoriasis
The ﬁrst part of the programme was to deﬁne the severity
of psoriasis. Based on clinical considerations and the later
generation of treatment goals, it was decided to use the
established scores BSA and PASI for the grading of
psoriasis symptoms (scaling, erythema and induration/
inﬁltration) and extent of lesions. It was further decided to
include an instrument to assess HRQOL in order to employ
an independent measure of patient-reported psoriasis
severity. Although there were country-speciﬁc differences
in the preferred validated instrument, it was consented by
the group to use the DLQI for the deﬁnitions.
Deﬁnition of plaque psoriasis severity
‘‘Psoriasis severity is deﬁned in two main categories:
mild versus moderate-to-severe.’’
(Delphi-result: vote 18/19 = agreement, round 1)
There was intense discussion among all experts on how
to deﬁne ‘‘mild’’ and ‘‘moderate to severe’’ plaque psoriasis
by using BSA, PASI and DLQI. There was agreement,
however, that a single unifying deﬁnition could not include
all clinical situations which may be present in a psoriasis
patient.
Deﬁnition of mild plaque psoriasis
BSA B 10 and PASI B 10 and DLQI B 10.
In accordance with existing guidelines, it is recom-
mended to treat mild psoriasis with topical agents.
‘‘If BSA B 10 and PASI B 10 indicates mild disease
but DLQI[10 indicates signiﬁcant impact on qual-
ity of life psoriasis can be considered moderate to
severe and systemic therapy may be initiated when
the patient’s disease cannot be controlled by topical
treatment.’’
(Delphi-result: vote 17/19 = agreement, round 4)
Mild plaque psoriasis can usually be controlled by top-
ical therapy. In refractory cases, the addition of photo-
therapy should be considered. However, patients with mild
psoriasis, as indicated by the somatic scores, BSA and
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quately controlled by topical therapy alone which, in
addition, may lead to a signiﬁcantly impaired quality of
life. These manifestations can include the following:
• involvement of visible areas,
• involvement of major parts of the scalp,
• involvement of genitals,
• involvement of palms and/or soles,
• onycholysis or onychodystrophy of at least two
ﬁngernails,
• pruritus leading to scratching and
• presence of single recalcitrant plaques.
The Consensus Group recognized that the presence of
disease manifestations listed above may alter the classiﬁ-
cation of mild disease (PASI B 10, BSA B 10,
DLQI B 10) to moderate to severe disease that warrants
phototherapy, systemic treatment, combination therapy or
special procedures including Excimer-laser or occlusive
topical treatment in individual cases. However, there was
an agreement not to include these items in a general deﬁ-
nition of plaque psoriasis severity.
Deﬁnition of ‘‘moderate to severe’’ plaque psoriasis
(BSA[10 or PASI[10) and DLQI[10
In accordance with existing guidelines, it is recom-
mended to treat moderate to severe psoriasis with photo-
therapy or systemic treatments.
‘‘If BSA[10 or PASI[10 indicates moderate to
severe disease but DLQI B 10 indicates no signiﬁ-
cant impact on quality of life psoriasis can be con-
sidered mild disease.’’
(Delphi-result: vote 17/19 = agreement, round 2)
Treatment phases for systemic therapy of plaque
psoriasis
Deﬁnition of induction and maintenance phase for systemic
treatment of psoriasis
The different drugs licensed for topical or systemic treat-
ment of psoriasis have different proﬁles related to onset of
action and overall efﬁcacy. For example, with the tumour
necrosis factor a-antagonist inﬂiximab, there is a fast onset
of action and an almost maximum therapeutic response by
week 10 of treatment [17]. On the other hand, methotrexate
or fumarates have a slower onset of action, and the maxi-
mum therapeutic response may only be achieved after
several months of treatment [19, 21]. It was found neces-
sary to provide a broader deﬁnition of induction and
maintenance therapy, taking into account the different
proﬁles of the drugs used.
Deﬁnition of induction phase
‘‘Induction phase is generally deﬁned as the treatment
period until week 16; however, depending on the type
of drug and dose regimen used, induction phase can
be extended until week 24 according to the decision
of the treating dermatologist.’’
(Delphi-result: vote 17/19 = agreement, round 2)
Deﬁnition of maintenance phase
‘‘Maintenance phase is deﬁned for all drugs as the
treatment period after the induction phase; therapeu-
tic success should be assessed in intervals according
to recommendations in the available guidelines.’’
(Delphi-result: vote 19/19 = agreement, round 1)
Treatment goals
The ultimate goal of any psoriasis treatment is to achieve
complete clearance of skin symptoms. However, the cur-
rent deﬁnition of treatment goals has to be based upon the
results achievable with available treatments as indicated by
the results of randomized controlled trials and the out-
comes observed in clinical practice.
In order to provide optimal therapy to patients, it
should be ensured that a therapy which was unable to
induce a certain degree of improvement is replaced by a
therapeutic alternative after a given period of time.
Therefore, the deﬁnition of treatment goals needs a
minimal degree of improvement (principle of the lowest
hurdle) and the drug-speciﬁc evaluation time points. The
assessment should ﬁrst be made at the end of induction
therapy (i.e. the time point at which the optimal clinical
response of a given drug can be expected) and later
during maintenance treatment in regular intervals which
may match with monitoring recommendations in the
respective guidelines.
There are three scenarios in which treatment goals need
to be deﬁned and in which advice is needed as to which
action has to be taken related to the outcome of the
judgement.
The ﬁrst is when treatment is successful, and the second
when treatment is unsuccessful. The third scenario repre-
sents an in-between response with a certain degree of
improvement which can neither be classiﬁed as success nor
failure.
If the treatment goal is not met, it is recommended to
modify therapy. Such modiﬁcation may be adjustment of
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or switching to another therapy.
Deﬁnition of treatment success after induction phase
‘‘If at the end of the induction phase a reduction in
PASI of C75% (DPASI C 75%) as compared to
disease severity at the time of treatment initiation has
been achieved, it is recommended to continue the
treatment regimen.’’
(Delphi-result: vote 19/19 = agreement, round 3)
Deﬁnition of treatment failure after induction phase
‘‘If at the end of the induction phase an improvement
of PASI of C50% (DPASI C 50%) as compared to
disease severity at the time of treatment initiation has
not been achieved, it is recommended to modify the
treatment regimen.’’
(Delphi-result: vote 19/19 = agreement, round 3)
In patients, where treatment response as assessed by
PASI was C50% but \75%, the impact of the remaining
disease on quality of life using the DLQI will be used as a
decision-making tool to either continue or to modify the
treatment regimen.
Deﬁnition of intermediate response to treatment
after induction phase
‘‘If at the end of the induction phase an improvement
of PASI of C50% but\75% (DPASI C 50%\75%)
as compared to disease severity at the time of treat-
ment initiation has been achieved, but DLQI B 5 has
not been achieved, it is recommended to modify the
treatment regimen.’’
‘‘If at the end of the induction phase a reduction in
PASI of C50% but\75% (DPASI C 50%\75%) as
compared to disease severity at the time of treatment
initiation and DLQI B 5 has been achieved, is rec-
ommended to continue with the treatment regimen.’’
(Delphi-result: vote 19/19 = agreement, round 3)
During the maintenance phase, treatment response
should be monitored regularly and compared to the situation
at baseline before treatment initiation. For most systemic
drugs, according to published guidelines, safety monitoring
is recommended at bimonthly intervals. During these visits,
treatment outcomes should be assessed by PASI and DLQI.
In relation to this assessment, the decision as to whether to
continue or to modify the therapeutic regimen should be
based (Fig. 2).
Deﬁnition of treatment success during maintenance
phase
‘‘If during maintenance therapy an improvement of
PASI of C75% (DPASI C 75%) as compared to
disease severity at the time of treatment initiation has
been achieved, it is recommended to continue with
the treatment regimen.’’
(Delphi-result: vote 17/19 = agreement, round 4)
Deﬁnition of treatment failure during maintenance
treatment
‘‘If during maintenance therapy an improvement of
PASI of C50% (DPASI C 50%) as compared to
disease severity at the time of treatment initiation has
not been achieved, it is recommended to modify the
treatment regimen.’’
(Delphi-result: vote 17/19 = agreement, round 4)
Deﬁnition of intermediate response to treatment
during maintenance phase
‘‘If during maintenance therapy an improvement of
PASI of C50% but of less than 75% (DPASI C 50%
\75%) as compared to disease severity at the time of
treatment initiation can be maintained, but DLQI B 5
has not been achieved, it is recommended to modify
the treatment regimen.’’
‘‘If during maintenance therapy an improvement of
PASI of equal or more than 50% but of less than 75%
(DPASI C 50% \75%) as compared to disease
severity at the time of treatment initiation can be
maintained and DLQI B 5 has been achieved, it is
recommended to continue with the treatment
regimen.’’
(Delphi-result: vote 17/19 = agreement, round 4)
Discussion
The management of chronic disease is dependent upon
clear ideas about the goals of treatment. This is due to the
considerable heterogeneity of the clinical expression of
diseases such as psoriasis and the varying response to any
therapy. In all clinical trials for the treatment of plaque
psoriasis published to date, there is no single drug or reg-
imen to which all patients respond. Variability in patient
response to any given drug is still poorly understood, but is
in part dictated by pharmacogenetics. Even when a treat-
ment response is seen, the degree of response/improvement
is variable among patients irrespective of dose and time of
6 Arch Dermatol Res (2011) 303:1–10
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temporal nature of drug response in that patients at one
time can show improvement to an administered drug, but
show only partial or even no response to the same drug
given at a later time-point. Biomarkers or predictors of
clinical response are not currently available for plaque
psoriasis.
Well-deﬁned treatment goals may be helpful to guide
physicians in their care of patients with psoriasis, thereby
obviating poor outcomes.
In a recent screening of publications in the rheumatol-
ogy literature concerning deﬁnitions of success or failure of
treatment particularly for rheumatoid arthritis, there was no
unifying consensus of a practical deﬁnition of either
treatment failure or clinical remission. The deﬁnitions used
ranged from complete absence of any clinical disease to
computer-generated numeric scales. It was concluded that
the variability in clinical deﬁnitions of either treatment
failure or remission seems to have been attributed mainly
to the time at which assessments were made, making it
difﬁcult to determine what these actually mean in clinical
practice [2]. A survey of experts in the management of
rheumatoid arthritis revealed that they were well informed
about recent concepts, but only two-thirds of them speci-
ﬁed remission as a major goal of treatment. The experts
attempted to reach treatment goals within 12–14 weeks of
initiation of treatment and were willing to modify therapy
otherwise. There was no consensus on how to assess out-
comes best as disease activity assessment by composite
scores was done by a majority of experts; however, one-
third of them preferentially relied upon their personal
clinical judgement [22]. This dilemma led to some initial
attempts to deﬁne criteria for treatment success or failure,
but no consensus has been published to date [5].
Despite the availability of a great number of treatment
options for psoriasis, surveys have shown that psoriasis
patients do not receive the optimal care that is necessary to
clear their skin symptoms and to improve their quality of
life [1, 6, 13]. A retrospective, patient-record analysis by
Gillard and Finlay [9] based on data from a primary-care
medical record database for the years 2002–2003 in the UK
demonstrated that only 245 (4%) of 6,120 patients with
psoriasis received either phototherapy or systemic therapy.
The large majority of patients (93.6%) received topical
treatment only [9]. In 2007, in private dermatological
practices in Germany, systemic treatments were prescribed
in only 31% of visits made by patients suffering from
moderate to severe psoriasis [1]. Patient-oriented studies of
members of psoriasis patient support associations have
shown low patient satisfaction with current treatment reg-
imens and high rates of non-compliance [6, 20, 27].
Thus, a deﬁnition of treatment goals was recently dis-
cussed for plaque psoriasis, and a ﬁrst attempt was made to
deﬁne a minimum degree of efﬁcacy which should be
achieved by topical, phototherapy or systemic therapy
evaluated at different time points [18]. The aim of this
consensusapproachwastoidentifyanddiscusstheneedsfor
patients with plaque psoriasis related to treatment outcomes
and to elaborate strategies which can be applied in general
without country-speciﬁc restrictions. To achieve this goal,
dermatologist from 19 European countries with a particular
interestinpsoriasismetinaconsensusconferenceforaface-
to-face discussion of a proposal produced by a steering
committee.Theoutcomeofthediscussionwastakenasbasis
of a following consensus step for which the well-established
Delphi procedure was employed. In the Delphi rounds,
questionnaires were answered by the group of experts, and
deﬁnitionsreﬁnedforthenextroundaccordingtovotingand
comments. After a completion of four rounds, the results
were regarded valid for publication as a consensus (Fig. 1).
It was necessary to ﬁrst deﬁne severity of psoriasis
before treatment goals were set.
There was agreement to separate plaque psoriasis into
two groups related to disease severity: mild and moderate
to severe. A further reﬁnement was achieved by using the
internationally accepted parameters BSA and PASI. As for
another widely used score, PGA, a major drawback is the
lack of a common deﬁnition, and therefore, this was not
found useful. Emphasis was on strength of an instrument to
assess quality of life in order to integrate an independent
parameter to assess psoriasis severity. Although a number
of different scales are available such as Skindex-29, Short-
Form 36 and others used in some countries as a primary
tool to measure HRQOL, it was decided to use the DLQI as
in the majority of countries, which is employed most often
[4]. The DLQI has been used worldwide in numerous
clinical trials and investigations on life quality and burden
of disease. In addition, it is available in all languages
spoken in the countries represented by the group and is
accessible through the internet (http://www.dermatology.
org.uk/quality/quality-dlqi.html)[ 7]. According to pub-
lished data, there is a deﬁnition of the different scores of
the DLQI and their impact on patients’ life which allows a
reliable grading of quality of life [11]. By using this deﬁ-
nition, a DLQI\5 indicates only mild impact on an
individual patients’ quality of life.
The deﬁnition of mild psoriasis follows the rule of tens
as proposed by Finlay and co-workers [8]. Reﬁning this
rule, the deﬁnition agreed upon by the Consensus Group is
BSA B 10 and PASI B 10 and DLQI B 10. Mild psoriasis
can normally be controlled by topical therapy. However,
certain clinical meaningful aspects of psoriasis can result in
a DLQI[10 while severity of skin symptoms and body
surface involvement is still mild. Such circumstances may
lead to a modiﬁcation of treatment, and psoriasis can be
considered moderate to severe.
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123Moderate to severe psoriasis is deﬁned as (BSA[10 or
PASI[10) and DLQI of [10. This severity of psoriasis
can no longer be controlled by topical therapies. In
patients, where body involvement and plaque characteris-
tics indicate moderate to severe disease but a DLQI is\10
indicating only limited impact on quality of life, an indi-
vidual therapeutic approach should be taken by the treating
dermatologist.
For the deﬁnition of treatment goals, it was necessary as
a ﬁrst step to deﬁne time points at which assessment of
disease severity should be made. Two main phases of
treatment were set: induction and maintenance. Induction
phase characterizes the time between the start of therapy
and the induction of remission. In the discussion, it became
apparent that there is a great heterogeneity in the ability of
different drugs to induce remission and to reach a plateau
of efﬁcacy. It was proposed, therefore, to deﬁne induction
phase until week 16 but to allow extension until week 24
when drugs or regimens with a known slow onset of action
are used. Maintenance phase was deﬁned as the treatment
phase after induction phase. As this period can vary from a
few weeks to several years dependent on individual patient
need, regular clinic visits to monitor safety and the
achievement of treatment goals should be scheduled
according to the recommendations given in the guidelines
[12, 16]. In clinical practice, this time frame for most
systemic drugs is 2 months.
The deﬁnition of treatment goals is meant to secure an
efﬁcacious treatment with regard to the control of clinical
symptoms and to substantiate improvement in quality of
life. Another most important consequence when deﬁning
treatment goals is the need for corrective action in the case
of the goal not being achieved. This is related to the
question of a meaningful clinical outcome and a minimum
requirement which must be fulﬁlled. The Consensus Group
elected to use the PASI together with the DLQI to deﬁne
treatment goals. It was further decided to generate separate
treatment goals for induction and maintenance phases.
Interestingly, during the Delphi process, it became clear
that the deﬁnitions for induction and maintenance phases
were similar.
The minimum requirement for the efﬁcacy of any
therapy was deﬁned to be an at least 50% reduction in the
baseline PASI, irrespective of the DLQI. If this is not met,
the treatment should be modiﬁed. Such modiﬁcation could
be a dose adjustment, addition of another therapy (com-
bination treatment) or transition to another drug or
modality. When PASI is reduced by at least 75%, the
treatment regimen can be continued. If the therapeutic
effect is a reduction in PASI of at least 50% but less than
75%, it is recommended to decide whether to modify the
therapeutic regimen according to DLQI. There was a
decision of the group of experts to set a DLQI B 5o r[5a s
a criterion when to modify treatment (Fig. 2) based on a
categorization study of the DLQI [11].
Itisimportant tostatethat division ofpsoriasis into either
mild or moderate to severe disease before initiation of
treatment will not be changed afterwards by the response to
the treatment chosen. It has been clearly shown that in the
majority of patients, stopping treatment will eventually
result in recurrence or relapse. In a minority of patients,
stopping treatment may result in deterioration of psoriasis
beyond the baseline severity known as rebound. The current
statusisthattherapiesusedforpsoriasiscanclearorimprove
skin symptoms, but are unable to either cure the disease or
induce long-lasting, disease-free remission. Even after
achievement ofcomplete skin clearance,the disease activity
may still be high resulting in rapid deterioration when
treatment is terminated or the dose of medication decreased.
Our consensus programme was able to deﬁne a number
of important items related to psoriasis therapy. Experts
from 19 European countries agreed on a: (1) grading of
plaque psoriasis into either mild or moderate to severe, (2)
deﬁnition of induction and maintenance phases and (3)
most importantly, treatment goals for both phases. This is a
unique approach which to date has been unexplored for
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123either plaque psoriasis or for other chronic inﬂammatory
diseases. The main objective of the consensus programme
was to improve patient care and help dermatologists regu-
larly assess outcomes achieved with established therapies. It
will be of major importance to familiarize the dermato-
logical community with such an approach, so it can be
utilized for daily practice.
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